The pandemic has pushed South Korea’s Celltrion to further expand beyond its core business of making “biosimilars,” or cheaper generic versions of name-brand “biologic” drugs and treatments. In October, the U.S. Food and Drug Administration granted emergency use authorization for Celltrion’s rapid COVID-19 testing kit, Sampinute, which promises to deliver results within 10 minutes and with a 94% sensitivity rate. The company is also developing a COVID-19 antibody treatment, to reduce the severity of the coronavirus once patients are infected, and has received South Korean regulatory approval to begin Phase III clinical trials of the drug.
- HealthThese Are the Health Care Companies Poised for Explosive GrowthOctober 18, 2018 10:31 PM UTC
- HealthNovartis Just Got Some Great News in Its Battle for Amgen’s Market ShareAugust 31, 2016 9:10 PM UTC
- TechSamsung Has a Best-Selling American Drug in Its CrosshairsMay 24, 2016 5:33 PM UTC
- FinanceOne of Korea’s Most Valuable Companies Could Be a Massive FraudMarch 18, 2016 4:23 PM UTC